SCHEMBL3303267

SCHEMBL3303267

Cc1cc(Nc2ccnc(Nc3ccc(C(=O)N4CCC(N(C)Cc5csc6ccccc56)CC4)cc3)n2)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 9/20 0.51
CHUK O15111 9/20 0.51
IKBKG Q9Y6K9 9/20 0.51
MEN1 O00255 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
PRKCZ Q05513 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CDK2 P24941 5/20 0.42
CDK1 P06493 4/20 0.42
PTK2 Q05397 1/20 0.41
SYK P43405 1/20 0.39
AURKA O14965 4/20 0.37
AURKB Q96GD4 2/20 0.37
ABL1 P00519 1/20 0.37
MAP4K4 O95819 1/20 0.37
PIM1 P11309 1/20 0.37
MAPK8 P45983 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3301574 0.87 IKBKB (0.46) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3302818 0.86 IKBKB (0.43) IKBKBCHUKIKBKGCDK2CDK1
SCHEMBL3301952 0.86 IKBKB (0.47) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3299557 0.85 IKBKB (0.48) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3295552 0.85 IKBKB (0.44) IKBKBCHUKIKBKGCDK2CDK1
SCHEMBL3337114 0.85 IKBKB (0.46) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3298132 0.84 IKBKB (0.46) IKBKBCHUKIKBKGCDK2CDK1
SCHEMBL3324217 0.84 IKBKB (0.46) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3301336 0.84 IKBKB (0.45) IKBKBCHUKIKBKGMEN1RECQL
SCHEMBL3301788 0.84 CDK1 (0.44) IKBKBCHUKIKBKGCDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE IKBKB 2/4885CHUK 1/4885IKBKG 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.